Evidence map›Paper›PMID 35357354›Full record

ArticleMedicine2022

The first report on effect of fecal microbiota transplantation as a complementary treatment in a patient with steroid-refractory Cronkhite-Canada syndrome: A case report.

Sun Young Kim, Jongbeom Shin, Jin-Seok Park, Boram Cha, Youjeong Seo, Soo-Hyun Park, Jung Hwan Lee, Jun-Seob Kim, Gyesook Kwon

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Challenges and Opportunities in Cronkhite-Canada Syndrome Research: A Bibliometric Analysis Based on the Web of Science Core Collection.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sun Young KimDigestive Disease Center, Department of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.
Jongbeom ShinDigestive Disease Center, Department of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.ORCID 0000-0001-6079-615
Jin-Seok ParkDigestive Disease Center, Department of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.
Boram ChaDigestive Disease Center, Department of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.
Youjeong SeoDepartment of Pathology, Inha University College of Medicine, Incheon, South Korea.
Soo-Hyun ParkDepartment of Hospital Medicine, Inha University College of Medicine, Incheon, South Korea.
Jung Hwan LeeDepartment of Hospital Medicine, Inha University College of Medicine, Incheon, South Korea.
Jun-Seob KimDepartment of Nano-Bioengineering, Incheon National University, Incheon, South Korea.
Gyesook KwonDigestive Disease Center, Department of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.
Inha University · KRInha University Hospital · KRIncheon National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCronkhite-Canada syndrome (CCS) is a rare non-hereditary disease of unknown etiology that is characterized by the appearance of multiple polyps in the entire gastrointestinal (GI) tract, except in the esophagus, with GI and non-GI symptoms. Various factors are associated with the pathogenesis of CCS. Immune dysregulation has been discussed as one of the pathogeneses of CCS, and dysbiosis of the gut microbiota can affect the immune system. Currently, standard treatment has not been established. PATIENT CONCERNS AND DIAGNOSIS: We present the treatment with fecal microbiota transplantation (FMT) in a 67-year-old male patient with steroid-refractory CCS who could not undergo anti-tumor necrosis factor-a treatment due to suspected tuberculosis infection.

interventionsFMT has recently attracted attention as a method of overcoming drug resistance through immunomodulatory effects through microbiome regulation. We collected the patient's stool samples before FMT and 8weeks after FMT. OUTCOMES: We analyzed the microbiome composition of patients by sequencing the V3-V4 region of the 16s rRNA gene (Miseq). After FMT, the number of episodes of diarrhea and hypoalbuminemia were also corrected. The Chao 1 index after FMT, which was significantly higher than that of donors before FMT, changed to a similar level for donors after FMT. Fusobacterium nucleatum, Pyramidobacter piscolens, and Campylobacter concisus disappeared after FMT, suggesting the presence of an association between gut microbiota and CCS. LESSONS: Furthermore, we provide the possibility that microbiome modulation by FMT could serve as a complementary treatment in patients with steroid-refractory CCS.

Indexed as

Fecal Microbiota TransplantationIntestinal PolyposisAgedFecesHumansMaleRNA, Ribosomal, 16SSteroidsRNA, Ribosomal, 16SSteroids

Identifiers

PMID35357354
PMCPMC11319313
OpenAlexW4220875750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.